After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...